Inflammatory burden index as a prognostic marker in patients with advanced gastric cancer treated with neoadjuvant chemotherapy and immunotherapy
BackgroundBlood inflammation index has been shown to correlate with the prognosis of patients with gastric cancer. However, few studies have compared the efficacy of existing blood inflammatory markers in predicting the prognosis of patients with locally advanced gastric cancer in combination with n...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1471399/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832592433638014976 |
|---|---|
| author | Jiao-Bao Huang Zhi-Yong Zhou Jun Lu Ji-Yun Zhu Bin Lai Sheng-Xun Mao Jia-Qing Cao |
| author_facet | Jiao-Bao Huang Zhi-Yong Zhou Jun Lu Ji-Yun Zhu Bin Lai Sheng-Xun Mao Jia-Qing Cao |
| author_sort | Jiao-Bao Huang |
| collection | DOAJ |
| description | BackgroundBlood inflammation index has been shown to correlate with the prognosis of patients with gastric cancer. However, few studies have compared the efficacy of existing blood inflammatory markers in predicting the prognosis of patients with locally advanced gastric cancer in combination with neoadjuvant chemotherapy and immunotherapy.ObjectiveThe objective of this study was to compare the prognostic value of existing commonly used blood inflammatory index in patients with advanced gastric cancer treated with neoadjuvant chemotherapy combined with immunotherapy.MethodsThe clinicopathological data of patients with advanced gastric cancer from three centers in China were analyzed retrospectively. Univariate COX regression analysis was used to analyze the independent risk factors of poor tumor regression and overall survival (OS) in this part of patients, and the predictive value of different inflammatory indexes on prognosis was compared by C-index index. Finally, Inflammatory burden index(IBI) was grouped by X-tile software, and Kaplan-Meier method was used to compare the survival difference between groups.ResultsA total of 163 patients were enrolled in this study. The median age was 63 years(56-68). The median cycle of neoadjuvant therapy was 4(3-4). The median survival time was 85.1%(1 years), 65.6%(2 years), and 47.4%(3 years).Univariate analysis showed that IBI was an independent risk factor for non-TR(residual tumor cells>50%) (HR=1.08,95%CI:1.00-1.45,p<0.001)and OS(HR=1.04,95%CI:1.03-1.05,p<0.001). IBI is the best predictor of OS (C-index: 0.82, 95% CI: 0.78-0.87) among all inflammatory indexes. The IBI cutoff value was 52.1. It was found that the high IBI group had a higher incidence of postoperative complications(32.1%vs14.3%, p=0.001), the proportion of non-TR patients was significantly higher than that of the low IBI group(64.3%vs35.7%, p =0.001), and the high IBI group had a significantly lower OS((47.6% vs 87.6%, p < 0.001).ConclusionIBI is the best inflammatory index to predict the prognosis of advanced gastric cancer treated with neoadjuvant chemotherapy combined with immunotherapy, which will help guide patients’ treatment decisions. This result still needs to be verified by large prospective studies. |
| format | Article |
| id | doaj-art-be7d7604c0a34fc3879f0822e3fc020f |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-be7d7604c0a34fc3879f0822e3fc020f2025-01-21T08:37:07ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-01-011510.3389/fimmu.2024.14713991471399Inflammatory burden index as a prognostic marker in patients with advanced gastric cancer treated with neoadjuvant chemotherapy and immunotherapyJiao-Bao Huang0Zhi-Yong Zhou1Jun Lu2Ji-Yun Zhu3Bin Lai4Sheng-Xun Mao5Jia-Qing Cao6Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaDepartment of Gastrointestinal Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaDepartment of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, ChinaDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Ningbo University, Ningbo, ChinaDepartment of Gastrointestinal Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaDepartment of Gastrointestinal Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaDepartment of Gastrointestinal Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaBackgroundBlood inflammation index has been shown to correlate with the prognosis of patients with gastric cancer. However, few studies have compared the efficacy of existing blood inflammatory markers in predicting the prognosis of patients with locally advanced gastric cancer in combination with neoadjuvant chemotherapy and immunotherapy.ObjectiveThe objective of this study was to compare the prognostic value of existing commonly used blood inflammatory index in patients with advanced gastric cancer treated with neoadjuvant chemotherapy combined with immunotherapy.MethodsThe clinicopathological data of patients with advanced gastric cancer from three centers in China were analyzed retrospectively. Univariate COX regression analysis was used to analyze the independent risk factors of poor tumor regression and overall survival (OS) in this part of patients, and the predictive value of different inflammatory indexes on prognosis was compared by C-index index. Finally, Inflammatory burden index(IBI) was grouped by X-tile software, and Kaplan-Meier method was used to compare the survival difference between groups.ResultsA total of 163 patients were enrolled in this study. The median age was 63 years(56-68). The median cycle of neoadjuvant therapy was 4(3-4). The median survival time was 85.1%(1 years), 65.6%(2 years), and 47.4%(3 years).Univariate analysis showed that IBI was an independent risk factor for non-TR(residual tumor cells>50%) (HR=1.08,95%CI:1.00-1.45,p<0.001)and OS(HR=1.04,95%CI:1.03-1.05,p<0.001). IBI is the best predictor of OS (C-index: 0.82, 95% CI: 0.78-0.87) among all inflammatory indexes. The IBI cutoff value was 52.1. It was found that the high IBI group had a higher incidence of postoperative complications(32.1%vs14.3%, p=0.001), the proportion of non-TR patients was significantly higher than that of the low IBI group(64.3%vs35.7%, p =0.001), and the high IBI group had a significantly lower OS((47.6% vs 87.6%, p < 0.001).ConclusionIBI is the best inflammatory index to predict the prognosis of advanced gastric cancer treated with neoadjuvant chemotherapy combined with immunotherapy, which will help guide patients’ treatment decisions. This result still needs to be verified by large prospective studies.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1471399/fullgastric cancerneoadjuvant therapyinflammatory indeximmunotherapyprognosis |
| spellingShingle | Jiao-Bao Huang Zhi-Yong Zhou Jun Lu Ji-Yun Zhu Bin Lai Sheng-Xun Mao Jia-Qing Cao Inflammatory burden index as a prognostic marker in patients with advanced gastric cancer treated with neoadjuvant chemotherapy and immunotherapy Frontiers in Immunology gastric cancer neoadjuvant therapy inflammatory index immunotherapy prognosis |
| title | Inflammatory burden index as a prognostic marker in patients with advanced gastric cancer treated with neoadjuvant chemotherapy and immunotherapy |
| title_full | Inflammatory burden index as a prognostic marker in patients with advanced gastric cancer treated with neoadjuvant chemotherapy and immunotherapy |
| title_fullStr | Inflammatory burden index as a prognostic marker in patients with advanced gastric cancer treated with neoadjuvant chemotherapy and immunotherapy |
| title_full_unstemmed | Inflammatory burden index as a prognostic marker in patients with advanced gastric cancer treated with neoadjuvant chemotherapy and immunotherapy |
| title_short | Inflammatory burden index as a prognostic marker in patients with advanced gastric cancer treated with neoadjuvant chemotherapy and immunotherapy |
| title_sort | inflammatory burden index as a prognostic marker in patients with advanced gastric cancer treated with neoadjuvant chemotherapy and immunotherapy |
| topic | gastric cancer neoadjuvant therapy inflammatory index immunotherapy prognosis |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1471399/full |
| work_keys_str_mv | AT jiaobaohuang inflammatoryburdenindexasaprognosticmarkerinpatientswithadvancedgastriccancertreatedwithneoadjuvantchemotherapyandimmunotherapy AT zhiyongzhou inflammatoryburdenindexasaprognosticmarkerinpatientswithadvancedgastriccancertreatedwithneoadjuvantchemotherapyandimmunotherapy AT junlu inflammatoryburdenindexasaprognosticmarkerinpatientswithadvancedgastriccancertreatedwithneoadjuvantchemotherapyandimmunotherapy AT jiyunzhu inflammatoryburdenindexasaprognosticmarkerinpatientswithadvancedgastriccancertreatedwithneoadjuvantchemotherapyandimmunotherapy AT binlai inflammatoryburdenindexasaprognosticmarkerinpatientswithadvancedgastriccancertreatedwithneoadjuvantchemotherapyandimmunotherapy AT shengxunmao inflammatoryburdenindexasaprognosticmarkerinpatientswithadvancedgastriccancertreatedwithneoadjuvantchemotherapyandimmunotherapy AT jiaqingcao inflammatoryburdenindexasaprognosticmarkerinpatientswithadvancedgastriccancertreatedwithneoadjuvantchemotherapyandimmunotherapy |